Top news of the week: 05.01.2021.
Career And Jobs
2020 Year in Review: Biopharma vs. COVID-19
Thanks to the pandemic caused by the SARS-CoV-2 coronavirus identified in late December 2019, 2020 was the year of COVID-19. It was a year of lockdowns and social distancing, a year of Zoom ...
It was the best of all possible worlds in the worst of all times for biotech in 2020. What comes now?
SVB Leerink’s Geoffrey Porges ran the numbers for biotech IPOs for all of 2020 and found that the industry rang out the old year with a record $13.5 billion raised from a chart-topping 81 ...
China approves its first COVID-19 vaccine
Chinese regulators granted a first approval for general use to a COVID-19 vaccine to China National Biotec Group’s (CNBG) BBIBP-CorV. “The NMPA granted conditional approval to the vaccine ...
India nears approval for two vaccines.
The United States and Britain this week diverged further in their vaccination strategies as American scientists, health experts and federal officials questioned or dismissed …
Member Spotlight: Q&A with Forma Therapeutics
In January, we spoke with Frank Lee, CEO, Forma Therapeutics.
AstraZeneca and Oxford’s Bumpy Partnership Hangs Over Covid Vaccine’s Future
The latest Covid-19 vaccine won authorization in the U.K. but continues to face challenges sown by confusing trial results.
In quick start to new year's M&A, Arvelle Therapeutics hands reins to Angelini as it nears EU approval for cenobamate
With a team of Axovant veterans leading the way, CNS startup Arvelle Therapeutics is nearing approval for licensed epilepsy med cenobamate in the EU after snagging an FDA approval in late ...
2020’s NDA list is packed with commercial firsts — from historic to haphazard. Have we reached a tipping point?
In drug R&D, a successful late-stage development program is like a widely shared celebrity love affair. Analysts will swoon over peak sales projections. Developers can hug themselves for a ...